Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Primary Lateral Sclerosis Clear all
No Longer Available No phase listed Expanded access

Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS

NCT05281484
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CNM-Au8
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
18 Years and older
U.S. locations
16
States / cities
Phoenix, Arizona • Orange, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Phase 3 Interventional Results available

Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS

NCT03505021
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Levosimendan, Placebo for levosimendan
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years to 120 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
48
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Jul 22, 2026, 5:58 AM EDT
Terminated Phase 3 Interventional

Continuation Study for Latozinemab

NCT06111014
View directory record Official record
Conditions
Neurodegenerative Diseases
Interventions
Latozinemab
Drug
Lead sponsor
Alector Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Active, not recruiting Phase 3 Interventional

Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

NCT05021536
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Placebo, AMX0035
Other · Drug
Lead sponsor
Amylyx Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
28
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Jul 22, 2026, 5:58 AM EDT
Not yet recruiting Not applicable Interventional

iBCI Optimization for Veterans With Paralysis

NCT05470478
View directory record Official record
Conditions
Spinal Cord Injury, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome, Muscular Dystrophy
Interventions
Mobile neural decoding platform (mobile iBCI)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

NCT05349721
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PTC857, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
Orange, California • San Francisco, California • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Jul 22, 2026, 5:58 AM EDT
Terminated Not applicable Interventional

A Pilot Study of the Utility of 3D Printed Masks for ALS Subjects

NCT03519880
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Custom Mask Interface
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Jul 22, 2026, 5:58 AM EDT
Recruiting No phase listed Observational

Spastic Paraplegia - Centers of Excellence Research Network

NCT06553976
View directory record Official record
Conditions
Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, SPG4, SPG5A, Spastic Paraplegia 4, Spastic Paraplegia 5A, Early Onset Hereditary Spastic Paraplegia, Neuromuscular Diseases, Spastic Paraplegia, Hereditary
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Miami, Florida • Iowa City, Iowa • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis [ALS]

NCT00005674
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Creatine
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional Results available

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)

NCT01849770
View directory record Official record
Conditions
Sporadic Amyotrophic Lateral Sclerosis
Interventions
Mexiletine, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Los Angeles, California • Iowa City, Iowa • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Jul 22, 2026, 5:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)

NCT00956501
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jul 22, 2026, 5:58 AM EDT
Terminated Phase 2 Interventional Results available

Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS)

NCT03679975
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Riluzole Oral Soluble film (ROSF) 50 mg
Drug
Lead sponsor
Aquestive Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Jul 22, 2026, 5:58 AM EDT
Completed No phase listed Observational

Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)

NCT00537641
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2015 · Synced Jul 22, 2026, 5:58 AM EDT
Not listed Phase 1Phase 2 Interventional

Determining the Safety of L-serine in ALS

NCT01835782
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
L-Serine
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
2
States / cities
Phoenix, Arizona • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Jul 22, 2026, 5:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-Invasive Measurement of Gastrointestinal (GI) Motility in Patients With Amyotrophic Lateral Sclerosis (ALS)

NCT00714805
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Christine Barr
Other
Eligibility
18 Years to 89 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2017 · Synced Jul 22, 2026, 5:58 AM EDT
Terminated Phase 1 Interventional

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS)

NCT04288856
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB078
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Jul 22, 2026, 5:58 AM EDT
Temporarily Not Available No phase listed Expanded access

Intermediate Expanded Access Protocol CNMAu8.EAP04

NCT06408727
View directory record Official record
Conditions
ALS, Amyotrophic Lateral Sclerosis, PALS
Interventions
CNM-Au8
Drug
Lead sponsor
Clene Nanomedicine
Industry
Eligibility
18 Years and older
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Chicago, Illinois • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
No Longer Available No phase listed Expanded access

IC14 for ALS Patients Expanded Access

NCT04309604
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
IC14
Biological
Lead sponsor
Implicit Bioscience
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jul 22, 2026, 5:58 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT05039099
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
AP-101, Placebo
Drug
Lead sponsor
AL-S Pharma
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 22, 2026, 5:58 AM EDT
Completed No phase listed Observational

Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis

NCT01592084
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2012 · Synced Jul 22, 2026, 5:58 AM EDT
Terminated Phase 3 Interventional Results available

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

NCT03948178
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Levosimendan
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years to 120 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Jul 22, 2026, 5:58 AM EDT
Not listed No phase listed Observational

Telespirometry in Amyotrophic Lateral Sclerosis (ALS)

NCT05106569
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Spirometry
Diagnostic Test
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Syracuse, New York • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Jul 22, 2026, 5:58 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Assessing Perceptual Effects of Interactive Tasks

NCT06828523
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Listener judgements of speech produced in different tasks
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 65 Years
Enrollment
1,300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 22, 2026, 5:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ALS Research Collaborative

NCT06885918
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS (Amyotrophic Lateral Sclerosis), ALS With Frontotemporal Dementia (ALS/FTD), Motor Neuron Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
ALS Therapy Development Institute
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2035
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Jul 22, 2026, 5:58 AM EDT